Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: Resistance to azithromycin and ceftriaxone and decreased susceptibility to ciprofloxacin

Journal of Health, Population and Nutrition

Volumn 25, Issue 2, 2007, Pages 158-167

  Rahman, Mahbubur ^a   Shoma, Shereen ^a   Rashid, Harunur ^a   El Arifeen, Shams ^a   Baqui, Abdullah H ^b   Siddique, A K ^a   Nair, G B ^a   Sack, David A ^a,b  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Azithromycin; Bangladesh; Ciprofloxacin; Drug resistance; E test; Microbial; Microbial sensitivity tests; Nalidixic acid; R plasmid; Shigella

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFTRIAXONE; CIPROFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BANGLADESH; DOSE RESPONSE; DRUG EFFECT; HEALTH SURVEY; HUMAN; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; SHIGELLA; SHIGELLOSIS; SPECIES DIFFERENCE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BANGLADESH; CEFTRIAXONE; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DYSENTERY, BACILLARY; HUMANS; MICROBIAL SENSITIVITY TESTS; SENTINEL SURVEILLANCE; SHIGELLA; SPECIES SPECIFICITY; TREATMENT OUTCOME;

SHIGELLA;

EID: 35348998558     PISSN: 16060997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kotloff KI, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999;77:651-66.
2. Ashkenazi S. Shigella spp. In: Yu VL, Merigan TC, Borriere SL, editors. Antimicrobial therapy and vaccines. Baltimore, MD: Williams & Wilkins, 1999:382-7.
3. Fontaine O. Antibiotics in the management of shigellosis in children: what role for quinolones? Rev Infect Dis 1989;11(Suppl):S1145-S50.
4. DuPont HL. Shigella species (bacillary dysentery). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and practice of infectious diseases. 5th ed. New York, NY: Livingstone, 2000;2:2363-9.
5. Keusch GT, Bennish ML. Shigellosis: recent progress, persisting problems and research issues. Pediatr Infect Dis 1989;8:713-9.
6. Bashualdo W, Arbo A. Randomized comparison of azithromycin versus cefixime for the treatment of shigellosis in children. Pediatr Infect Dis J 2003;22:374-7.
7. Bermish ML, Salam MA, Hossain MA, Myaux J, Khan EH, Chakraborty J et al. Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin Infect Dis 1992;14:1055-60.
8. Niyogi SK, Pazhani GP. Multiresistant Shigella species isolated from childhood diarrhea cases in Kolkata, India. Jpn J Infect Dis 2003;56:33-4.
9. Rahman M, Mauff G, Levy J, Couturier M, Pulverer G, Glasdorff N et al. Detection of 4-quinolone resistance mutation in gyrA gene of Shigella dysenteriae type 1 by PCR. Antimicrob Agents Chemother 1994;38:2488-91.
10. Replogle ML, Fleming DW, Cieslak PR. Emergence of antimicrobial-resistant shigellosis in Oregon. Clin Infect Dis 2000;30:515-9.
11. Sack RB, Rahman M, Yunus M, Khan EH. Antimicrobial resistance in organisms causing diarrheal diseases. Clin Infect Dis 1997;24(Suppl 1):S102-S5.
12. Hossain MA, Rahman M, Ahmed S, Malek A, Sack RB, Albert MJ. Increasing frequency of mecillinam-resistant Shigella isolates in urban Dhaka and rural Matlab, Bangladesh: a 6-year observation. J Antimicrob Chemother 1998;42:99-102.
13. Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin: a double-blind, randomized, controlled trial. Ann Intern Med 1997;126:697-703.
14. Varsano I, Elditz-Marcus T, Nussinotich M, Elian I. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J Pediatr 1991;118:627-32.
15. Ahmed J, Gangopadhyay J, Kundu M, Sinha AK. Mechanisms of quinolone resistance in clinical isolates of Shigella dysenteriae. Antimicrob Agents Chemother 1999;43:2333-4.
16. Bhattacharya SK, Sarkar K, Nair GB, Faruque AS, Sack DA. Multidrug-resistant Shigella dysenteriae type 1 in South Asia. Lancet Infect Dis 2003;3:755.
17. Kelly MT, Brenner J, and Farmer JJ, III. Enterobacteriaceae. In: Lennette EH, Balows A, Hausler J, Jr, Shadomy HJ, editors. Manual of clinical microbiology, 4th ed. Washington, DC: American Society for Microbiology, 1985:263-77.
18. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. Wayne, PA: Clinical Laboratory Standards Institute, 2005.
19. Bradford PA Extended-spectrum ß-lactamases in 21st century: characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51
20. Neu HC, Cherubin CE, Longo ED, Flouton B, Winter J. Antimicrobial resistance and R-factor transfer among isolates of Salmonella in the northeastern United States: a comparison of human and animal isolates. J Infect Dis 1975;132:617-22.
21. Portnoy DA, Mosley SL, Falkow S. Characterization of plasmids and plasmid-associated determinants of Yersinia enterocolitica pathogenesis. Infect Immun 1981;31:775-82.
22. Rahman M, Shoma S, Rashid H, Siddique AK, Nair GB, Sack DA. Extended-spectrum beta-lactamase-mediated third-generation cephalosporin resistance in Shigella isolates in Bangladesh. J Antimicrb Chemother 2004;54:846-7.
23. Salam MA, Bennish ML. Therapy of shigellosis: randomized double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 1988;113:901-7.
24. Skov R, Frimodt-Moller N, Blomstrom A, Espersen F. Comparison of different MIC methods and establishment of zone diameter breakpoints for mecillinam, using NCCLS methodology (abstract). In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto), Canada, September 17-20, 2000. Washington, DC: American Society for Microbiology, 2000:136.
25. Hossain MA, Hasan KZ, Albert MJ. Shigella carriers among non-diarrhoeal children in an endemic area of shigellosis in Bangladesh. Trop Geogr Med 1994;46:40-2.
26. Carbon C. Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Clin Infect Dis 1998;27:28-32.
27. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use - safety report. Pediatr Infect Dis J 1997;16:127-9.
28. Sur D, Niyogi SK, Sur S, Datta KK, Takeda Y, Nair GB et al. Multidrug-resistant Shigella dysenteriae type 1: forerunners of a new epidemic strain in eastern India? Emerg Infect Dis 2003;9:404-5.
29. Aarestrup FM, Wiuff C, Mølbak K, Threlfall EJ. Is it time to change fluoroquinolone breakpoints for Salmonella spp. (letter)? Antimicrob Agents Chemother 2003;47:827-9.
30. Chandel DS, Chaudhury R. Enteric fever treatment failures: a global concern. Emerg Infect Dis 2001;7:762-3
31. Threlfall EJ, Ward LR. Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype Typhi, United Kingdom. Emerg Infect Dis 2001;7:448-50.
32. Talukder KA, Khajanchi BK, Islum MA, Dutta DK, Islam Z, Safa A et al. Genetic relatedness of ciprofloxacin-resistant Shigella dysenteriae type 1 isolated in South Asia. J Antimicrob Chemother 2004;54:730-4.
33. Dutta S, Kawamura Y, Ezaki T, Nair GB, Ida KI, Yoshida SI. Alteration in the gyrA subunit DNA gyrase and parC subunit of topoisomerase IV in quinolone-resistant Shigella dysenteriae serotype 1 clinical isolates from Kolkata, India. Antimicrob Agents Chemother 2005;49:1660-1.
34. Tran JH, Jacoby JA. Mechanism of plasmid-mediated quinolone resistance. PNAS 2002;99:5638-42.
35. Salam MA, Seas C, Khan WA, Bennish ML. Treatment of shigellosis: IV. Cefixime is ineffective in shigellosis in adults. Ann Intern Med 1995;123:505-8.
36. Huang IF, Chiu CH, Wang MH, Wu CY, Hsieh KS, Chiou CC. Outbreak of dysentery associated with ceftriaxone-resistant Shigella sonnei: first report of plasmid-mediated CMY-2-type AmpC betalactamase resistance in S. sonnei. J Clin Microbiol 2005;43:2608-12.
37. Mirelis B, Novarro F, Miro E, Mesa RJ, Coll P, Prats G. Community transmission of extended-spectrum beta-lactamases. Emerg Infect Dis 2003;9:1024-5.